Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 09/01/2025 at 06:59, 6 months 21 days ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis unveils Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting associated with obesity. The new program broadens potential and value-creation opportunities globally

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
BRIEF

published on 08/28/2025 at 07:05, 6 months 25 days ago

Biophytis lance son essai clinique de phase 3 sur la sarcopénie

Biophytis Belgique Essai Clinique Sarcopénie EMA
BRIEF

published on 08/28/2025 at 07:05, 6 months 25 days ago

Biophytis Gains Regulatory Approval for Phase 3 Sarcopenia Trial

Biophytis Regulatory Approval Clinical Trial Sarcopenia Phase 3
REGULATED PRESS RELEASE

published on 08/28/2025 at 07:00, 6 months 25 days ago

Biophytis obtient l’autorisation de l’EMA et des autorités belges pour démarrer son essai clinique de phase 3 dans la sarcopénie
Biophytis obtient l’autorisation de l’EMA et des autorités belges pour démarrer son essai clinique de phase 3 dans la sarcopénie. La société se prépare à recruter des patients pour cette étude majeure

Biophytis Essai Clinique Sarcopénie Autorisation EMA
REGULATED PRESS RELEASE

published on 08/28/2025 at 07:00, 6 months 25 days ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, marking a significant milestone in developing therapies for muscle loss in aging individuals

Biophytis Sarcopenia Phase 3 EMA Belgian Regulatory Approval
PRESS RELEASE

published on 08/28/2025 at 06:59, 6 months 25 days ago

Biophytis obtient l’autorisation de l’EMA et des autorités belges pour démarrer son essai clinique de phase 3 dans la sarcopénie
Biophytis obtient l’autorisation de l’EMA et des autorités belges pour démarrer son essai clinique de phase 3 dans la sarcopénie. Étape majeure dans le développement de thérapies pour la perte musculaire liée à l’âge

Biophytis Essai Clinique Sarcopénie Autorisation EMA
PRESS RELEASE

published on 08/28/2025 at 06:59, 6 months 25 days ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, enabling patient enrolment in Belgium and collaboration with European centers

Biophytis Sarcopenia Phase 3 EMA Approval Belgian Regulatory Approval
BRIEF

published on 08/05/2025 at 23:05, 7 months 16 days ago

Biophytis Secures €1 Million Non-Dilutive Bond Financing

Biophytis Bond Financing Shareholder Impact Non-dilutive OBA101 Program
BRIEF

published on 08/05/2025 at 23:05, 7 months 16 days ago

Biophytis assure 1 million d'euros de financement obligataire

Biophytis Dilution Actionnaires Financement Obligataire Hexagon Capital Fund OBA101 Développement
REGULATED PRESS RELEASE

published on 08/05/2025 at 23:00, 7 months 16 days ago

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million
Biophytis secures a non-dilutive bond financing line of up to €1 million with Hexagon Capital Fund to support OBA101 program development and strengthen cash position

Biophytis Financing Hexagon Capital Fund OBA101 Program Non-dilutive Bond

Published on 03/20/2026 at 23:00, 1 day 20 hours ago

Cypher Announces Private Placement
Published on 03/20/2026 at 21:30, 1 day 22 hours ago

Sky Gold Sets Options
Published on 03/20/2026 at 21:15, 1 day 22 hours ago

Earthwise Minerals Announces Private Placement
Published on 03/20/2026 at 13:30, 2 days 6 hours ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 7 hours ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals

View all ACCESSWIRE

Published on 03/22/2026 at 18:22, 1 hour 28 minutes ago

Test news - please ignore EN
Published on 03/22/2026 at 12:23, 7 hours 27 minutes ago

Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 21 hours ago

Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 22 hours ago

Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 22 hours ago

Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion

View all EQS

Published on 03/20/2026 at 19:00, 2 days ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days ago

AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 1 hour ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 1 hour ago

Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
Published on 03/20/2026 at 17:45, 2 days 2 hours ago

Cie du Bois Sauvage : Jaarverslag 2025

View all LES ECHOS COMFI WIRE

News